rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARMP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Armata Pharma earnings beat by $0.17, revenue topped estimates
      Nov 13Investing.comARMP
      Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates
      Nov 12Yahoo FinanceKRYSARMP
      Armata Pharmaceuticals receives two U.S. patents for therapies
      Oct 7Investing.comARMP
      JonesTrading Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)

      Tipranks Press Release.

      Sep 28The Globe and MailARMP
      Armata secures new U.S. funding for AP-SA02 Phase 3

      Tipranks Press Release.

      Sep 24The Globe and MailARMP
      Armata Pharmaceuticals Stock Slides after Pentagon Funding - Armata Pharmaceuticals (AMEX:ARMP)

      Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.

      Sep 23BenzingaARMP
      Armata receives $3.7m DoW funding for phase 3 drug trial
      Sep 23Investing.comARMP
      Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
      Sep 23Yahoo FinanceARMP
      Analysts Offer Insights on Healthcare Companies: RxSight (RXST) and Armata Pharmaceuticals (ARMP)

      Detailed price information for Rxsight Inc (RXST-Q) from The Globe and Mail including charting and trades.

      Sep 23The Globe and MailRXSTARMP
      H.C. Wainwright reiterates Armata Pharmaceuticals stock rating on phage data
      Sep 22Investing.comARMP
      Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
      Sep 21Yahoo FinanceARMP
      Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation

      Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S.

      Sep 14Yahoo FinanceARMP
      Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

      Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureu

      Sep 14Yahoo FinanceARMP
      Armata Pharmaceuticals stock rises on FDA breakthrough designation
      Sep 14Investing.comARMP
      Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      --Armata Pharmaceuticals, Inc., a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate...

      Sep 10NasdaqARMP
      Armata Pharmaceuticals publishes phage research findings
      Sep 3Investing.comARMP
      Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

      --Armata Pharmaceuticals, Inc., a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

      Sep 3NasdaqARMP

      This is the newest page. Registered accounts read further back.